This editorial addresses the evolving landscape of DNA methylation profiling in CNS tumors, bridging the gap between molecular classification and practical bedside application. While methylation-based diagnostics have revolutionized tumor subtyping, determining their true 'clinical utility' remains a complex challenge. My editorial highlights the necessity of balancing high-resolution molecular data with actionable treatment pathways, ensuring that precision medicine remains accessible and meaningful for patient management